The FDA is working to conclude its review by the end of May 2024. The Food and Drug Administration (FDA) has informed Moderna that its review of the Biologics License Application (BLA) for mRNA ...
The FDA has delayed a key meeting to determine the formula for the next COVID-19 vaccines amid a spike in cases linked to the ...
First, a bit of background on Moderna's RSV candidate. RSV generally causes cold-like symptoms, but the virus could be severe ...
Moderna (NASDAQ:MRNA) shares are down just over 1% in early Friday trading after the company said the FDA has informed it that it will not be able to meet the May 12 PDUFA for their RSV vaccine ...
Moderna reported better-than-expected 1Q24 revenue of $167 million and its pipeline looks promising. Read my earnings ...